Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation

Journal of Clinical Investigation

Volumn 116, Issue 8, 2006, Pages 2094-2104

  Stratis, Athanasios ^a   Pasparakis, Manolis ^a,b   Rupec, Rudolf A ^c   Markur, Doreen ^a   Hartmann, Karin ^a   Scharffetter Kochanek, Karin ^d   Peters, Thorsten ^d   Van Rooijen, Nico ^e,f   Krieg, Thomas ^a   Haase, Ingo ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; CLODRONIC ACID; GAMMA INTERFERON; HYBRID PROTEIN; I KAPPA B; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GRANULOCYTE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; KERATINOCYTE; MACROPHAGE; MAST CELL; MIGRATION INHIBITION; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; SKIN DISEASE; SKIN INFLAMMATION; T LYMPHOCYTE;

ANIMALS; CLODRONIC ACID; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; I-KAPPA B KINASE; INFLAMMATION; LIPOSOMES; MACROPHAGES; MICE; MICE, KNOCKOUT; PHENOTYPE; PSORIASIS; SKIN; T-LYMPHOCYTES;

EID: 33746760161     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27179     Document Type: Article

References (61)

1. Lever, W.F., and Schaumburg-Lever, G. 1983. Histopathology of the skin. J.B. Lippincott Company. Philadelphia, Pennsylvania, USA. 848 pp.
2. Schön, M., et al. 2000. Critical role of neutrophils for the generation of psoriais skin lesions in flaky skin mice. J. Invest. Dermatol. 114:976-983.
3. Schön, M., Behmenburg, D., Denzer, D., and Schön, M.P. 2001. Pathogenic function of IL-1 beta in psoriasiform skin lesions of flaky skin (fsn/fsn) mice. Clin. Exp. Immunol. 123:505-510.
4. Schön, M.P., Detmar, M., and Parker, C.M. 1997. Murine psoriasis-like disorder induced by naive CD4+ T-cells. Nat. Med. 3:183-188.
5. Blessing, M., Schirmacher, P., and Kaiser, S. 1996. Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions. J. Cell Biol. 135:227-239.
6. Carroll, J.M., Romero, M.R., and Watt, F.M. 1995. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell. 83:957-968.
7. Cook, P.W., et al. 1997. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J. Clin. Invest. 100:2286-2294.
8. Bullard, D.C., et al. 1996. A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 93:2116-2121.
9. Sano, S., et al. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11:43-49.
10. Zenz, R., et al. 2005. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 437:369-375.
11. Schon, M.P. 1999. Animal models of psoriasis - what can we learn from them? J. Invest. Dermatol. 112:405-410.
12. Ellis, C.N., et al. 1991. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N. Engl. J. Med. 324:277-284.
13. Gottlieb, S.L., et al. 1995. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1:442-447.
14. Wrone-Smith, T., and Nickoloff, B.J. 1996. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98:1878-1887.
15. Nickoloff, B.J., and Wrone-Smith, T. 1999. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am. J. Pathol. 155:145-158.
16. Boyman, O., et al. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J. Exp. Med. 199:731-736.
17. Schon, M.P., and Boehncke, W.H. 2005. Psoriasis. N. Engl. J. Med. 352:1899-1912.
18. Pasparakis, M., et al. 2002. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature. 417:861-866.
19. Claassen, I., Van Rooijen, N., and Claassen, E. 1990. A new method for removal of mononuclear phagocytes from heterogeneous cell populations in vitro, using the liposome-mediated macrophage 'suicide' technique. J. Immunol. Methods. 134:153-161.
20. van Rooijen, N., Bakker, J., and Sanders, A. 1997. Transient suppression of macrophage functions by liposome-encapsulated drugs. Trends Biotechnol. 15:178-185.
21. Qian, Q., Jutila, M.A., Van Rooijen, N., and Cutler, J.E. 1994. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J. Immunol. 152:5000-5008.
22. Wang, H., et al. 2006. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J. Clin. Invest. 116:2105-2114. doi:10.1172/JCI27180.
23. Walzog, B., Scharffetter-Kochanek, K., and Gaehtgens, P. 1999. Impairment of neutrophil emigration in CD18-null mice. Am. J. Physiol. 276:G1125-G1130.
24. van den Oord, J.J., and Wolf-Peeters, C.D. 1994. Epithelium- lining macrophages in psoriasis. Br. J. Dermatol. 130:589-594.
25. Boehncke, W.H., Wortmann, S., Kaufmann, R., Mielke, V., and Sterry, W. 1995. A subset of macrophages located along the basement membrane ("lining cells") is a characteristic histopathological feature of psoriasis. Am. J. Dermatopathol. 17:139-144.
26. Nickoloff, B.J. 2000. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J. Investig. Dermatol. Symp. Proc. 5:67-73.
27. Cao, W., Lee, S.H., and Lu, J. 2005. CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells. Biochem. J. 385:85-93.
28. Scharffetter-Kochanek, K., et al. 1998. Spontaneous skin ulceration and defective T cell function in CD18 null mice. J. Exp. Med. 188:119-131.
29. Mosser, D.M. 2003. The many faces of macrophage activation. J. Leukoc. Biol. 73:209-212.
30. Huang, S., et al. 1993. Immune response in mice that lack the interferon-gamma receptor. Science. 259:1742-1745.
31. Robert, C., and Kupper, T.S. 1999. Inflammatory skin diseases, T cells and immune surveillance. N. Engl. J. Med. 341:1817-1828.
32. Nickoloff, B.J., et al. 2000. Is psoriasis a T-cell disease? Exp. Dermatol. 9:359-375.
33. Cook, P.W., Brown, J.R., Cornell, K.A., and Pittelkow, M.R. 2004. Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also associated with synovitis. Exp. Dermatol. 13:347-356.
34. Weber-Matthiesen, K., and Sterry, W. 1990. Organization of the monocyte/macrophage system of normal human skin. J. Invest. Dermatol. 95:83-89.
35. Koga, T., Duan, H., Urabe, K., and Furue, M. 2002. In situ localization of CD83-positive dendritic cells in psoriatic lesions. Dermatology. 204:100-103.
36. Lowes, M.A., et al. 2005. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. U. S. A. 102:19057-19062.
37. Thepen, T., et al. 2000. Resolution of cutaneous inflammation after local elimination of macrophages. Nat. Biotechnol. 18:48-51.
38. Lind, M.H., et al. 2004. Tumor necrosis factor receptor 1- mediated signaling is required for skin cancer development induced by NF-kappaB inhibition. Proc. Natl. Acad. Sci. U. S. A. 101:4972-4977.
39. Gugasyan, R., et al. 2004. The transcription factors c-rel and RelA control epidermal development and homeostasis in embryonic and adult skin via distinct mechanisms. Mol. Cell. Biol. 24:5733-5745.
40. Piguet, P.F. 1993. TNF and the pathology of the skin. Res. Immunol. 144:320-326.
41. Kauffman, C.L., et al. 2004. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123:1037-1044.
42. Munder, M., Mallo, M., Eichmann, K., and Modolell, M. 1998. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J. Exp. Med. 187:2103-2108.
43. Piskin, G., Sylva-Steenland, R.M., Bos, J.D., and Teunissen, M.B. 2006. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176:1908-1915.
44. Lee, E., et al. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199:125-130.
45. Alber, G., et al. 2006. Induction of immunity and inflammation by interleukin-12 family members. Ernst Schering Res. Found. Workshop. 56:107-127.
46. Trepicchio, W.L., and Dorner, A.J. 1998. The therapeutic utility of interleukin-11 in the treatment of inflammatory disease. Expert Opin. Investig. Drugs. 7:1501-1504.
47. Hart, P.H., Cooper, R.L., and Finlay-Jones, J.J. 1991. IL-4 suppresses IL-1 beta, TNF-alpha and PGE2 production by human peritoneal macrophages. Immunology. 72:344-349.
48. Trepicchio, W.L., et al. 1999. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. 104:1527-1537.
49. Ghoreschi, K., et al. 2003. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9:40-46.
50. Schon, M., Denzer, D., Kubitza, R.C., Ruzicka, T., and Schon, M.P. 2000. Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice. J. Invest. Dermatol. 114:976-983.
51. Miura, H., Sano, S., Higashiyama, M., Yoshikawa, K., and Itami, S. 2000. Involvement of insulin-like growth factor-I in psoriasis as a paracrine growth factor: dermal fibroblasts play a regulatory role in developing psoriatic lesions. Arch. Dermatol. Res. 292:590-597.
52. Dimon-Gadal, S., et al. 2000. Increased oxidative damage to fibroblasts in skin with and without lesions in psoriasis. J. Invest. Dermatol. 114:984-989.
53. Krueger, G.G., Jederberg, W.W., Ogden, B.E., and Reese, D.L. 1978. Inflammatory and immune cell function in psoriasis: II. Monocyte function, lymphokine production. J. Invest. Dermatol. 71:195-201.
54. Toruniowa, B., and Jablonska, S. 1988. Mast cells in the initial stages of psoriasis. Arch. Dermatol. Res. 280:189-193.
55. Schubert, C., and Christophers, E. 1985. Mast cells and macrophages in early relapsing psoriasis. Arch. Dermatol. Res. 277:352-358.
56. Mease, P.J., et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 356:385-390.
57. Chaudhari, U., et al. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 357:1842-1847.
58. Gottlieb, A.B., et al. 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51:534-542.
59. Leonardi, C.L., et al. 2003. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349:2014-2022.
60. Krueger, G.G., et al. 2002. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 47:821-833.
61. Van Rooijen, N. 1989. The liposome-mediated macrophage 'suicide' technique. J. Immunol. Methods. 124:1-6.